BORTEZOMIB TEVA 1 MG

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

BORTEZOMIB

Verfügbar ab:

ABIC MARKETING LTD, ISRAEL

ATC-Code:

L01XX32

Darreichungsform:

POWDER FOR SOLUTION FOR INJECTION

Zusammensetzung:

BORTEZOMIB 1 MG

Verabreichungsweg:

I.V

Verschreibungstyp:

Required

Hergestellt von:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Therapiebereich:

BORTEZOMIB

Anwendungsgebiete:

Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

Berechtigungsdatum:

2017-07-04